Inhaled insulin: new technology, new possibilities

S Bellary, A H Barnett

Research output: Contribution to journalReview articlepeer-review


The prevalence of diabetes is reaching epidemic proportions with an increasing need for new therapies. Several new therapies are in development and amongst these is inhaled insulin. Inhaled insulin is a novel way of delivering insulin and has been shown to have an efficacy comparable to subcutaneous insulin in patients with both type 1 and type 2 diabetes. Several inhaled insulin delivery systems are currently in development and the first of these, Exubera has recently been granted license in Europe and in the USA. In this article we review the efficacy and safety profile of Exubera and discuss its potential place in the management of diabetes.

Original languageEnglish
Pages (from-to)728-34
Number of pages7
JournalInternational Journal of Clinical Practice
Issue number6
Publication statusPublished - Jun 2006


  • Administration, Cutaneous
  • Administration, Inhalation
  • Administration, Oral
  • Diabetes Mellitus
  • Drug Costs
  • Humans
  • Hypoglycemia
  • Hypoglycemic Agents
  • Insulin
  • Lung Diseases
  • Patient Satisfaction
  • Randomized Controlled Trials as Topic
  • Respiratory Function Tests
  • Treatment Outcome
  • Weight Gain
  • Journal Article
  • Review


Dive into the research topics of 'Inhaled insulin: new technology, new possibilities'. Together they form a unique fingerprint.

Cite this